Optic Neuritis Treatment Guidelines

First-Line Treatment

High-dose intravenous methylprednisolone at 1000 mg/day for 3 days is the recommended first-line treatment for optic neuritis, according to the American Academy of Neurology 1
Treatment should be initiated promptly, as delays beyond 2 weeks are associated with poorer outcomes, with a strength of evidence level I 1, 2
Higher doses of IV methylprednisolone (up to 30 mg/kg, not exceeding 1000 mg/day) may be used in certain cases, with a moderate level of evidence 1

For optic neuritis associated with Systemic Lupus Erythematosus (SLE), combination therapy with pulse IV methylprednisolone and IV cyclophosphamide is recommended, with a high level of evidence 1
For Neuromyelitis Optica Spectrum Disorder (NMOSD)-associated optic neuritis, initial treatment remains IV methylprednisolone at 1000 mg/day for 3-5 days, with a moderate level of evidence 2
Long-term immunosuppressive therapy is typically required to prevent relapses in NMOSD-associated optic neuritis, with a high level of evidence 2

Plasma exchange (PLEX) should be considered in severe cases not responding to IV steroids, with a moderate level of evidence 1, 2
Rituximab (RTX) is recommended for refractory cases, particularly in NMOSD-associated optic neuritis, with a high level of evidence 1, 2
Mycophenolate mofetil (MMF) may be used as an alternative immunosuppressant, with a low level of evidence 3, 2

Regular ophthalmological evaluations including visual acuity, visual fields, and funduscopy are necessary to monitor treatment response, with a high level of evidence 1, 2
Visual-evoked potentials may detect bilateral optic nerve damage before it becomes clinically apparent, with a moderate level of evidence 1
MRI of the brain and orbits with contrast is essential for diagnosis and to rule out other conditions, with a high level of evidence 1

Relapses are common (50-60%) during corticosteroid dose reduction, highlighting the need for maintenance immunosuppressive therapy in some cases, with a high level of evidence 1
Patients with MOG-IgG antibodies should be tested after the first recurrence of optic neuritis, as standard MS treatments may worsen outcomes in these patients, with a moderate level of evidence 3
For patients with antiphospholipid antibodies not responding to immunosuppressive therapy, anticoagulation may be considered, with a low level of evidence 1

In pediatric optic neuritis, treatment should be adjusted based on weight (typically 30 mg/kg/day of methylprednisolone), with a moderate level of evidence 1

Obtain MRI of both orbits AND brain with gadolinium contrast at presentation to evaluate optic nerve enhancement and identify demyelinating brain lesions, as recommended by the American College of Radiology 4, 5
MRI findings are incorporated into the McDonald criteria for MS diagnosis, establishing dissemination in space and time, according to the American College of Radiology 4, 5
Test for MOG-IgG antibodies after the first recurrence of optic neuritis, as MOG antibody disease requires different management, and standard MS disease-modifying therapies can worsen outcomes in MOG-positive patients, as reported in the World of Neurosurgery 6

Use IV methylprednisolone with or without IVIG for MOG-positive optic neuritis, as recommended in the World of Neurosurgery 6
For refractory cases, rituximab is the most consistently effective immunomodulatory therapy, according to the World of Neurosurgery 6
Mycophenolate mofetil or azathioprine can be used as steroid-sparing maintenance immunosuppressants for MOG-positive optic neuritis, as reported in the World of Neurosurgery 6